The combined therapy of Herceptin and Iressa is additive in suppression of EGFR and HER2 activation as well as exerting its anti-proliferative effect, consistent with the report that combination of targeted therapies against both EGFR and HER2 is more effective that single agents in breast cancer [33]. This evidence concerns the gene EGFR and breast cancer.